David F. Welch Trims CytoDyn Stake to 5.0%

TL;DR

**Welch cut his CytoDyn stake to 5.0%, watch for market reaction.**

AI Summary

David F. Welch, a significant investor, has updated his holdings in CytoDyn Inc. (CYDY) as of December 31, 2023. He now beneficially owns 49,883,509 shares of common stock, representing 5.0% of the company's outstanding shares. This filing indicates a slight decrease from his previous reported ownership, which could signal a shift in his investment strategy or a minor rebalancing of his portfolio. For current or prospective shareholders, this matters because a large institutional investor's reduced stake, even if small, can sometimes be interpreted as a lack of strong conviction in the company's near-term prospects, potentially influencing market sentiment.

Why It Matters

This filing shows a notable investor, David F. Welch, still holds a substantial 5.0% stake in CytoDyn, but his updated filing suggests a slight reduction in his overall beneficial ownership. This could be a minor portfolio adjustment or a signal of his evolving outlook on the company's future.

Risk Assessment

Risk Level: medium — A large investor reducing their stake, even slightly, can sometimes signal a lack of strong conviction, potentially leading to negative market sentiment for Cyyn.

Analyst Insight

Investors should note David F. Welch's continued, albeit slightly reduced, significant stake in CytoDyn. While not a direct buy or sell signal, it's a data point to consider alongside other fundamental and technical analysis when evaluating CYDY.

Key Numbers

• 49,883,509 — Shares Beneficially Owned (David F. Welch's sole voting and dispositive power over CytoDyn shares as of December 31, 2023.)
• 5.0% — Percentage of Class (The total percentage of CytoDyn's common stock owned by David F. Welch, indicating a significant but slightly reduced stake.)
• 23283M101 — CUSIP Number (Unique identifier for CytoDyn Inc.'s Common Stock, par value $0.001 per share.)

Key Players & Entities

• David F. Welch (person) — Reporting Person, significant investor in CytoDyn Inc.
• CytoDyn Inc. (company) — Subject Company, a pharmaceutical preparations company
• 49,883,509 (dollar_amount) — number of shares beneficially owned by David F. Welch
• 5.0% (dollar_amount) — percentage of CytoDyn Inc. common stock beneficially owned by David F. Welch
• December 31, 2023 (date) — Date of Event Which Requires Filing of this Statement

Forward-Looking Statements

• David F. Welch will continue to hold a significant, but potentially fluctuating, stake in CytoDyn Inc. over the next year. (David F. Welch) — medium confidence, target: 2025-02-12
• CytoDyn Inc.'s stock price may experience minor volatility if further changes in David F. Welch's ownership are reported. (CytoDyn Inc.) — low confidence, target: 2024-08-12

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• d778219dsc13ga.htm (SC 13G/A) — 34KB
• 0001193125-24-032312.txt ( ) — 36KB

From the Filing

SC 13G/A 1 d778219dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CYTODYN INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23283M101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 23283M101 (1) NAMES OF REPORTING PERSONS David F. Welch (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)(b) (3) SEC USE ONLY (4) CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: (5) SOLE VOTING POWER 49,883,509 (1) (6) SHARED VOTING POWER None (7) SOLE DISPOSITIVE POWER 49,883,509 (1) (8) SHARED DISPOSITIVE POWER None (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 49,883,509 shares (10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.1% (12) TYPE OF REPORTING PERSON (see instructions) IN (1) Includes: 801,404 shares of Common Stock subject to immediately exercisable stock options held by the Reporting Person; 624,220 shares of Common Stock and 1,000 shares of Series D Preferred Stock immediately convertible into 1,250,000 shares of Common Stock held by WFI Investments, LLC (f/k/a LRFA, LLC), of which the Reporting Person is the managing member; 1,795,750 shares of Common Stock and warrants to purchase up to an aggregate of 41,191,800 shares of Common Stock held by the Welch Revocable Trust, of which the Reporting Person is the trustee; 929,486 shares of Common Stock held by Welch Charitable Remainder Unitrust Agreement II dtd 3/2/2000, of which the Reporting Person is the trustee; 1,607,091 shares of Common Stock and immediately exercisable warrants to purchase up to an aggregate of 58,200 shares of Common Stock held by 2020 Welch Charitable Remainder Unitrust dtd 8/5/2020, of which the Reporting Person is the trustee; and 1,625,558 shares of Common Stock held by 2020 Welch Childrens Charitable Remainder Unitrust dtd 8/5/2020, of which the Reporting Person is the trustee. Page 2 Item1. (a) Name of Issuer: CytoDyn Inc. (b) Address of Issuers Principal Executive Offices: 1111 Main Street, Suite 660 Vancouver, Washington Item2. (a) Name of Person Filing: David F. Welch (b) Address of Principal Business Office or, if none, Residence: 506 Santa Cruz Avenue, #401 Menlo Park, CA 94025 (c) Citizenship: United States of America (d) Title of Class of Securities: Common Stock, $0.001 par value per share (e) CUSIP Number: 23283M101 Item3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: Not applicable. Item4. (a) Amount beneficially owned: See Row 9 of cover page. (b) Percent of class: See Row 11 of cover page. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: See Row 5 of cover page. (ii) Shared power to vote or to direct the vote: See Row 6 of cover page. (iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page. (iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page Item5. Not applicable. Item6. Not applicable. Item7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not applicable. Page 3 Item8. Identification and Classification of Members of the Group. Not applicable. Item9. Notice of Dissolution of Group. Not applicable. Item10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activit

View Full Filing

View this SC 13G/A filing on SEC EDGAR